Evidence map›Paper›PMID 36984761›Full record

ArticleMetabolites2023

A Novel Approach on the Use of Samples from Faecal Occult Blood Screening Kits for Metabolomics Analysis: Application in Colorectal Cancer Population.

Oihane E Albóniga, Joaquín Cubiella, Luis Bujanda, María Encarnación Blanco, Borja Lanza, Cristina Alonso, Beatriz Nafría, Juan Manuel Falcón-Pérez

Abstract read
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Oihane E AlbónigaMetabolomics Platform, CICbioGUNE-BRTA, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Bizkaia Technology Park, 48160 Derio, Spain.ORCID 0000-0002-3663-6794
Joaquín CubiellaDepartment of Gastroenterology, Instituto de Investigación Sanitaria Galicia Sur, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Complexo Hospitalario Universitario de Ourense, 32005 Ourense, Spain.ORCID 0000-0002-9994-4831
Luis BujandaDepartment of Gastroenterology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Biodonostia Health Research Institute, Donosti Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastián, Spain.
María Encarnación BlancoOWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.ORCID 0000-0003-4032-8003
Borja LanzaOWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.
Cristina AlonsoOWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.ORCID 0000-0002-2019-678X
Beatriz NafríaClinical Biochemistry Department, Biodonostia Health Research Institute Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, 20014 San Sebastian, Spain.
Juan Manuel Falcón-PérezMetabolomics Platform, CICbioGUNE-BRTA, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Bizkaia Technology Park, 48160 Derio, Spain.ORCID 0000-0003-3133-0670

Funding

Instituto de Salud Carlos III DTS19/00160
6 · The paper itself

Abstract

The incidence of colorectal cancer (CRC) is increasing, and currently it is the third most common cancer. Early CRC diagnosis is still difficult and relies on an invasive colonoscopy and tissue biopsy. The globally observed tendency demands non-invasive, specific, and accurate diagnostic tools for early diagnosis and prognosis. In this work, the main aim was to evaluate for the first time the feasibility of using extracts from the non-invasive sample collection from faecal occult blood (FOB) kits for its use in metabolomics studies taking advantage in this way of the high sensitivity of this technology. Then, a cohort of 131 samples from control individuals (CTL), adenoma (AD) and CRC patients were analysed using a semitargeted approach by ultra-high-performance liquid chromatography-time-of-flight-mass spectrometry (UHPLC-ToF-MS). Multivariate and univariate statistical analysis revealed that cholesteryl esters (ChoE) with polyunsaturated fatty acids (PUFAs) together with FOB were relevant metabolites that could clearly separate CRC patients from AD and CTL individuals, whereas the metabolic profiles of CTL and AD were very similar. These results are in agreement with previous findings and reveal the advantage of using the same FOBT samples for several analyses, which would facilitate sample collection and improve direct connection between FOB measurements and metabolomics analysis. Although the sample size and the number of metabolites should be enhanced to cover a wider range of metabolites, alterations in lipid metabolism clearly point out for future perspectives.

Indexed as

cholesteryl esterscolorectal cancerFOB screening kitslipidssemitargeted metabolomics

Identifiers

PMID36984761
PMCPMC10055627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.